Pediatric Endocrinology in India

03/12/2025

25/11/2025

https://whatsapp.com/channel/0029VamlZb3AzNbrYHd82W2a/224

23/11/2025

Can you spot the three mistakes in the measurement of sitting height?

Answers at
https://whatsapp.com/channel/0029VamlZb3AzNbrYHd82W2a/216

19/11/2025

Why GnRH agonists (and not antagonists) are used for treating CPP?*

GnRH agonists, when given continuously, initially stimulate the pituitary but then desensitize and down-regulate GnRH receptors, leading to sustained suppression of LH and FSH.
This stable, long-acting suppression effectively halts pubertal progression, making GnRHa the standard of care for CPP.

GnRH antagonists produce immediate receptor blockade, but their effect is short-acting, requires very frequent dosing, and cannot maintain steady long-term suppression needed for ongoing control of CPP.
Therefore, antagonists are not routinely used for CPP treatment

https://whatsapp.com/channel/0029VamlZb3AzNbrYHd82W2a

19/11/2025

https://whatsapp.com/channel/0029VamlZb3AzNbrYHd82W2a

18/11/2025

Why are te**es not enlarged more than 6 mL in testotoxicosis (LH-receptor activating mutation), unlike in central precocious puberty?

Because testotoxicosis activates only the LH receptor, leading to Leydig-cell stimulation without FSH rise.
The predominant bulk of testicular size comes from the seminiferous tubules, which are under FSH control.

Since FSH is not elevated in testotoxicosis, the seminiferous tubules do not enlarge, so testicular volume stays ≤6 mL.
In central precocious puberty, FSH is high, causing seminiferous-tubule growth and testicular enlargement.